Related Experiment Video
Updated: May 29, 2026
Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice
Published on: March 30, 2022
Stem cell therapy for the treatment of myocardial infarction
1Department of Cardiovascular Diseases, Gasthuisberg University, Hospital Leuven, Herestraat 49, B-3000 Leuven, Belgium.
Insights
Autologous bone marrow cell therapy shows promise for improving heart function after myocardial infarction. However, current evidence is mixed, indicating it
Area of Science:
- Cardiology
- Regenerative Medicine
- Stem Cell Biology
Background:
- Severe myocardial infarction (MI) leads to unfavorable outcomes despite optimal treatments, with significant risks of mortality and heart failure.
- Adverse left ventricular remodeling and incomplete myocardial salvage necessitate novel therapeutic strategies.
- Emerging research on the heart's endogenous repair capabilities has spurred interest in stem cell-based therapies for ischemic injury.
Purpose of the Study:
- To critically review randomized controlled trials on intracoronary autologous bone marrow cell transfer in acute myocardial infarction.
- To explore underlying mechanisms, practical considerations, and future challenges of this therapeutic approach.
- To assess the safety, feasibility, and efficacy of progenitor cell therapy in MI patients.
Main Methods:
- Systematic review and critical analysis of published randomized controlled clinical trials.
- Focus on intracoronary administration of autologous bone marrow cells.
- Evaluation of safety, feasibility, and impact on left ventricular function and remodeling.
Main Results:
- Intracoronary progenitor cell transfer is confirmed as safe and feasible in acute myocardial infarction.
- Efficacy data suggests potential for improved left ventricular function recovery beyond standard care, but results are modest and inconsistent.
- No evidence supports true cardiomyogenesis (heart muscle cell regeneration) with current methods.
Conclusions:
- Progenitor cell therapy is not yet ready for routine clinical implementation in ischemic heart disease due to complexity, cost, and uncertainties.
- Further research is required to develop strategies for effective cardiomyocyte regeneration combined with myocardial protection.
- Future studies should focus on optimizing cell-based approaches for enhanced cardiac repair and functional recovery.
Abstract:
Despite timely reperfusion and subsequent optimal postinfarct pharmacotherapy and device-based treatment, the outcome in patients with severe myocardial infarction remains unfavourable. Myocardial salvage is incomplete, resulting in adverse left ventricular remodeling with concomitant morbidity and mortality. The combined risk of recurrent myocardial infarction, death or readmission for heart failure amounts to 25 % within the first year, highlighting the need for additional treatment strategies. Recent and rapidly evolving insights in cardiac biology, recognizing endogenous repair capabilities of the adult human heart, paved the path towards progenitor or stem cell based cardiac protection and repair strategies following ischemic injury. We critically report on the major randomized controlled clinical trials published so far concerning intracoronary transfer of autologous bone marrow cells in the setting of acute myocardial infarction. Moreover, underlying mechanisms, practical aspects, remaining questions and future challenges are highlighted. Taken together, these trials confirm the safety and feasibility of intracoronary progenitor cell transfer in the setting of myocardial infarction. Efficacy data suggests its potential to improve left ventricular function recovery beyond current state of the art therapy, but results are mixed, modest at best and do not support true cardiomyogenesis. Hence, due to its complexity, costs and remaining uncertainties, it is still too early to implement progenitor cell therapy in its current form in standard treatment strategies for ischemic heart disease. Future studies on strategies for cardiomyocyte regeneration in combination with myocardial protection are needed.
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
01:14Myocarditis III: Medical Management